Equities

Shenzhen YHLO Biotech Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Shenzhen YHLO Biotech Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)13.67
  • Today's Change0.01 / 0.07%
  • Shares traded3.16m
  • 1 Year change-15.62%
  • Beta1.1040
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shenzhen YHLO Biotech Co Ltd is a China-based company primarily engaged in the provision of in vitro diagnostic instruments. The Company mainly focuses on the research, development, production, and sales of in vitro diagnostic instruments and related reagents based on chemiluminescence immunoassay, as well as the agency sales of some non-self-produced medical device products. The Company's products are used in fields such as autoimmunity, reproductive health, diabetes, and infectious diseases. The Company's products are sold in domestic and international markets.

  • Revenue in CNY (TTM)1.90bn
  • Net income in CNY143.32m
  • Incorporated2008
  • Employees1.75k
  • Location
    Shenzhen YHLO Biotech Co LtdNo. 65, Baolong 2nd RoadBaolong Neighbourhood, Longgang DistrictSHENZHEN 518116ChinaCHN
  • Phone+86 75 584821649
  • Fax+86 75 526473319
  • Websitehttps://www.szyhlo.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cowealth Medical China Co Ltd777.03m-11.37m6.74bn203.00--6.10--8.67-0.0285-0.02851.972.780.52063.321.003,827,724.00-0.71684.75-0.93936.3516.3820.19-1.385.562.65--0.022933.36-14.05-2.15-41.58-16.312.73--
Shanghai Sanyou Medical Co Ltd512.33m64.88m7.08bn514.0094.333.41--13.820.22510.22511.586.220.22130.52636.23996,747.102.516.732.867.7873.3583.3111.3325.253.81--0.020418.72-1.485.06-88.00-34.86-14.02--
Beijing Chunlizhengda Mdicl Instr Co Ltd1.05bn255.37m7.80bn1.24k34.122.95--7.400.67290.67292.787.780.29950.64373.48851,792.407.269.448.5511.5264.9972.1524.2325.015.09--0.0000724.89-33.32-1.18-55.01-11.99-17.97--
Shenzhen YHLO Biotech Co Ltd1.90bn143.32m7.81bn1.75k52.942.88--4.100.2580.2583.434.740.45751.104.011,086,410.003.2313.954.0619.5762.9555.777.0519.421.403.240.271433.21-2.0218.05-15.0622.9035.88--
HOB Biotech Group Corp Ltd387.48m36.43m9.04bn529.00243.9910.77--23.340.58380.58386.1713.230.39381.507.30732,482.303.707.244.418.6457.8764.539.4016.211.0714.220.080542.822.019.20-22.24-10.4334.88--
Shinva Medical Instrument Co Ltd9.58bn508.92m9.37bn8.14k18.461.20--0.97880.8370.83715.7812.910.62862.204.501,177,051.003.304.126.278.9724.4625.095.245.610.8863--0.12421.150.08742.715.75-4.2914.3026.58
Data as of Feb 11 2026. Currency figures normalised to Shenzhen YHLO Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

6.88%Per cent of shares held by top holders
HolderShares% Held
Hwabao WP Fund Management Co., Ltd.as of 30 Sep 202511.42m2.00%
China Merchants Fund Management Co., Ltd.as of 30 Jun 20255.18m0.91%
Rongtong Fund Management Co., Ltd.as of 30 Jun 20254.10m0.72%
China Southern Asset Management Co., Ltd.as of 30 Jun 20253.41m0.60%
China Asset Management Co., Ltd.as of 30 Jun 20253.34m0.59%
Penghua Fund Management Co., Ltd.as of 30 Jun 20253.32m0.58%
Bosera Asset Management Co., Ltd.as of 30 Jun 20252.55m0.45%
GF Fund Management Co., Ltd.as of 30 Jun 20252.25m0.40%
Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 20252.00m0.35%
The Vanguard Group, Inc.as of 07 Jan 20261.63m0.29%
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.